Old drug, new tricks: The unexpected effect of doxazosin on high-density lipoprotein

Circulation Research

Volumn 101, Issue 2, 2007, Pages 116-118

  Remaley, Alan T ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ADAPTOR PROTEIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; APOLIPOPROTEIN A1; CHLORTALIDONE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DOXAZOSIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; NORADRENALIN; PHOSPHATASE; PROBUCOL; PROTEIN KINASE B BETA;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOACCUMULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; GENE EXPRESSION REGULATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CHO CELLS; CHROMATIN IMMUNOPRECIPITATION; CRICETINAE; CRICETULUS; DOXAZOSIN; GENE EXPRESSION; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MUTATION; PROTEIN BINDING; RECEPTORS, ADRENERGIC, ALPHA-1; RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC;

EID: 34547589762     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.107.157404     Document Type: Editorial

References (27)

1. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th edition. Washington DC: AACC Press;2000:391-416.
2. Wu CA, Tsujita M, Hayashi M, Yokoyama S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem. 2004;279:30168-30174.
3. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci. 2005;62:2150-2160.
4. Suzuki S, Nishimaki-Mogami T, Tamehiro N, Inoue K, Arakawa R, Abe-Dohmae S, Tanaka AR, Ueda K, Yokoyama S. Verapamil increases the apolipoprotein- mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol. 2004;24:519-525.
5. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005;25:1193-1197.
6. Iwamoto N, Abe-Dohmae S, Ayaori M, Tanaka N, Kusuhara M, Ohsuzu F, Yokoyama S. ATP binding cassette transporter A1 gene transcription is downregulated by the Activator Protein (AP) 2 α: Doxazosin inhibits AP2α and increases high-density lipoprotein biogenesis being independent of α1-adrenoreceptor blockade. Circ Res. 2007;101:156-165.
7. Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug. Hypertens Res. 2007;30:301-306.
8. Bhardwa J, Goldstraw M, Tzortzis S, Kirby R. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2007;8:1337-1344.
9. Alberti C. Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. Eur Rev Med Pharmacol Sci. 2007;11:59-64.
10. Yono M, Foster HE, Shin D, Mane S, Latifpour J. Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. Life Sci. 2005;77:470-479.
11. Ames RP, Kiyasu JY. α-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins. J Clin Pharmacol. 1989;29:123-127.
12. Rabkin SW, Huff MW, Newman C, Sim D, Carruthers SG. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension. 1994;24:241-248.
13. Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J. 1996;131:966-973.
14. Grimm RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, Lews C, McDonald R, Schoenberger J, Stamler J. Long-term effects of plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. J Am Med Assoc. 1996;275:1549-1556.
15. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens. 2001;14:908-913.
16. Derosa G, Cicero AF, D'Angelo A, Tinelli C, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Fogari R. Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. J Cardiovasc Pharmacol. 2006;47:508-512.
17. Kinoshita M, Shimazu N, Fujita M, Fujimaki Y, Kojima K, Mikuni Y, Horie E, Teramoto T. Doxazosin, an α1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens. 2001;14:267-270.
18. Maheux P, Facchini F, Jeppesen J, Greenfield MS, Clinkingbeard C, Chen YD, Reaven GM. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens. 1994;7:416-424.
19. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press. 1998;7:39-45.
20. Simonsen U, Prieto D, Nyborg NC, Mulvany MJ. Effects of doxazosin on functional alterations of isolated coronary arteries from cholesterol-fed rabbits. J Pharm Pharmacol. 1996;48:607-614.
21. Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS. Pharmacological exploitation of the α1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem. 2004;47:4453-4462.
22. Schaefer EJ, Asztalos BF. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Curr Opin Cardiol. 2007;22:373-378.
23. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:276-294.
24. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000;105:513-520.
25. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res. 2004;45:1410-1417.
26. Major cardiovascular events in hypertensive paitents randomized to doxazosin vs chlorthalidone: the hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Group. J Am Med Assoc. 2000:283:1967-1975.
27. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira KI, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T. SREBP-2- and LXR-driven dual promoter regulation of hepatic ABCA1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem. 2007. In press.